A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, PARALLEL GROUP, DOSE-RANGING STUDY OF PF-07976016 TO ASSESS SAFETY AND EFFICACY IN ADULT PARTICIPANTS WITH OBESITY
Primary Objective
To study a new anti-obesity medication
Description
To study effectiveness, safety and tolerability of a new investigational medication (PF-07976016) in adults with obesity
Details
Age
Adult
Eligibility
18-74 years old; BMI of 30 or greater; Do not have type 1 or type 2 diabetes; Have not taken any weight loss medications in last 12 weeks
Locations
Anschutz Health and Wellness
Outpatient CTRC
Principal Investigator
Dan Bessesen
Study ID
Protocol Number: 24-2153
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers